Quick Answer
NEUROONE MEDICAL TECHNOLOGIES Corp reported R&D Expense of $4.98 million for fiscal year 2025.
NEUROONE MEDICAL TECHNOLOGIES Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.98M | -1.6% |
| 2024 | $5.07M | -27.0% |
| 2023 | $6.94M | +40.8% |
| 2022 | $4.93M | +25.6% |
| 2021 | $3.93M | +89.1% |
| 2020 | $2.08M | +35.7% |
| 2019 | $1.53M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.39M | +18.6% | +17.5% |
| June 30, 2025 | $1.18M | -1.0% | -21.7% |
| March 31, 2025 | $1.51M | +18.6% | +28.9% |
| December 31, 2024 | $1.17M | -21.0% | -1.9% |
| June 30, 2024 | $1.19M | -36.8% | -6.2% |
| March 31, 2024 | $1.27M | -25.4% | -14.1% |
| December 31, 2023 | $1.48M | -5.1% | -21.6% |
| June 30, 2023 | $1.89M | +54.4% | +10.9% |
- NEUROONE MEDICAL TECHNOLOGIES Corp showed a decrease of -1.6% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, NEUROONE MEDICAL TECHNOLOGIES Corp’s r&d expense has grown by 225.9% (from $1.53 million to $4.98 million).
- The most recent figure is from NEUROONE MEDICAL TECHNOLOGIES Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: